Julie Delyon

Julie Delyon
Saint Louis Hospital

MD PhD

About

133
Publications
5,303
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,169
Citations
Citations since 2017
109 Research Items
1003 Citations
2017201820192020202120222023050100150200250
2017201820192020202120222023050100150200250
2017201820192020202120222023050100150200250
2017201820192020202120222023050100150200250
Introduction
Julie Delyon currently works in the Onco-Dermatology Department, Saint-Louis Hospital, Paris Cité University, Paris, France

Publications

Publications (133)
Article
The cyclic AMP (cAMP) signaling pathway is critical in melanocyte biology for regulating differentiation. It is downregulated by phosphodiesterase (PDE) enzymes, which degrade cAMP itself. In melanoma evidence suggests that inhibition of the cAMP pathway by PDE type 4 (PDE4) favors tumor progression. For example, in melanomas harboring RAS mutation...
Article
Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanomas harboring KIT alteration. The primary endpoint was the response rate (complete response (CR) or partial response (PR) following RECIST criteria) at 6 months. Pharmacodynamic stud...
Article
Background: Kaposi sarcoma is a vascular tumor related to herpesvirus-8 and is promoted by immunosuppression. For the last 15 years, HIV patients have had access to organ transplantation. The dual immunosuppression of HIV and immunosuppressive treatments might increase the risk and severity of Kaposi sarcoma. Methods: We conducted a multicentric...
Article
Full-text available
Kaposi’s sarcoma (KS) is a common neoplasm in Eastern and central Africa reflecting the spread of human gammaherpesvirus-8 (HHV-8), now considered a necessary causal agent for the development of KS. The endemic KS subtype can follow an aggressive clinical course with ulcerative skin lesions with soft tissue invasion or even bone or visceral involve...
Article
Full-text available
During the acute phase of the COVID-19 pandemic, hospitals faced a challenge to manage patients, especially those with other comorbidities and medical needs, such as cancer patients. Here, we use Process Mining to analyze real-world therapeutic pathways in a cohort of 1182 cancer patients of the Lausanne University Hospital following COVID-19 infec...
Article
Full-text available
Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first-line ICI in this clinical context and explore the potential contribution of total tumor metabolic...
Article
Full-text available
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results of the BOLT study. However, to date, no real-world study of sonidegib has been reported. An observational, retrospective, single-centre study (PaSoS study) was conducted. The primary objective was to evaluate the effica...
Article
Increasing the efficacy of immune checkpoint blockade therapy while mitigating toxicity is one of the major challenges in oncology research. In this issue of Cancer Cell, Hailemichael et al. provide a strong rationale for the combination of IL-6 blockade and dual inhibition of CTLA-4 and PD-1 to overcome this issue.
Article
Full-text available
Background: Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed. Objectives: In this study, we aimed to evaluate the diagnostic accuracy of FDG PET/CT to define the extent of disease in KS. Methods: Consecutive patients wit...
Article
Background Although the treatment of iatrogenic and HIV-related Kaposi sarcoma is well defined and mostly based on restoring immune function, the treatment of classic and endemic Kaposi sarcoma is less well established. Chemotherapy or interferon α is used for patients with extensive cutaneous or visceral Kaposi sarcoma, but tolerance might be poor...
Article
Introduction Le diagnostic de mélanome est l’un des points les plus cruciaux de la prise en charge dermatologique. Récemment, le développement d’algorithmes de deep learning pour le diagnostic de tumeurs cutanées malignes et en particulier de mélanome amorce une révolution dans le diagnostic par le dermatologue. Cependant, la plupart des algorithme...
Article
Introduction L’inflammation chronique peut initier la mutagenèse via les dérivés réactifs de l’oxygène et amplifier la tumorogenèse via certaines protéines comme NF-kB. L’inflammation cutanée chronique est un facteur de risqué établi de carcinome épidermoïde (CE). Le rôle de l’inflammation aiguë est mal élucidé. Nous rapportons 4 cas de plusieurs C...
Article
Introduction Le sonidégib est un inhibiteur de la voie de signalisation sonic hedgehog (Shh), indiqué pour le traitement des patients atteints de carcinome basocellulaire localement avancé (CBCla). L’étude de phase II (BOLT) a montré un taux de réponse globale (RG) de 56 % (intervalle de confiance à 95 % (IC95) = 43–68) à 42 mois après évaluation c...
Article
Full-text available
Background The number of patients with a history of melanoma who are waiting a solid organ transplantation (SOT) is increasing. Few recommendations exist on the timing to transplantation after melanoma diagnosis. The aim of this study was to assess the melanoma recurrence-free survival after pretransplant melanoma (PTM). Methods We conducted a mul...
Article
Full-text available
PurposeDabrafenib plus trametinib combination has greatly improved survival in BRAFV600mut metastatic melanoma patients. However, data regarding the influence of pharmacokinetic markers in real-life patients are lacking. In this study, we aimed to explore dabrafenib and trametinib pharmacokinetic impact on progression-free survival (PFS), duration...
Article
Introduction Les inhibiteurs de point de contrôle immunitaire (ICI), anti-CTLA-4 et anti-PD-1, ont révolutionné la prise en charge de certains cancers. Les myosites survenant sous ICI (ICI-Myo) sont des effets secondaires rares mais potentiellement graves. Leur description est récente et leur prise en charge n’est pas codifiée. L’objectif de cette...
Article
Introduction Les inhibiteurs de point de contrôle immunitaire (ICI), anti-CTLA-4 et anti-PD-1, ont révolutionné la prise en charge de certains cancers. Les myosites induites par les ICI (ICI-Myo) sont des effets secondaires rares mais potentiellement graves. Leur survenue nécessite un arrêt de l’immunothérapie et un traitement immunomodulateur dans...
Article
Full-text available
Background: Although several studies described the clinical course of epidemic and post-transplant Kaposi's Sarcoma (KS), the lack of large cohorts of classic/endemic KS, precluded such characterization. Methods: We used multi-state modelling in a retrospective monocentric study to evaluate global disease evolution and identify risk factors for...
Article
Full-text available
In locally advanced dermatofibrosarcoma protuberans (DFSP), imatinib mesylate has been described as an efficient neoadjuvant therapy. This retrospective study included patients with locally advanced DFSP who received neoadjuvant TKI (imatinib or pazopanib) from 2007 to 2017 at Saint Louis Hospital, Paris. The primary endpoint was the evaluation of...
Article
Purpose: In BRAFV600MUT metastatic melanoma, cyclin-D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of CDK4 inhibitors. In this phase I-II study, we aimed to establish the maximum tolerated dose (MTD) of palbociclib when added to vemurafenib. Patients and methods: BRAFV600E/KMUT m...
Article
Full-text available
Background Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration of irAEs in the literature is often incomplete. Methods To investigate reporting and incidence of late-onset and long-lasting irAEs, we reviewed all registration trials...
Article
Immune checkpoint inhibitors have revolutionized the treatment landscape for a number of cancers over the last few decades. Nevertheless, a majority of patients still do not benefit from these treatments. Such patient-specific lack of response can be predicted, in part, from the immune phenotypes present in the tumor microenvironment. We provide a...
Article
Wnt/β-catenin signaling plays crucial roles in melanocyte biology and may be implicated in melanoma progression. In this study, we retrospectively examined a real-life cohort of melanomas mutated for β-catenin (CTNNB1), in association or not with a MAPK mutation (of BRAF or NRAS), and analyzed their clinical, histopathological, and molecular charac...
Article
Objectives: The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyze the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICI) rechallenge. Methods: We conducted a nationwide retrospective study between April 2018 and March 2020 in...
Article
Full-text available
Background Tumor molecular deciphering is crucial in clinical management. Pan-cancer next-generation sequencing panels have moved towards exhaustive molecular characterization. However, because of treatment resistance and the growing emergence of pharmacological targets, tumor-specific customized panels are needed to guide therapeutic strategies.Ob...
Article
Introduction La voie de signalisation Wnt/β-caténine joue un rôle crucial durant la mélanogénèse en contrôlant la prolifération et la différentiation des précurseurs mélanocytaires. Une mutation activatrice de la β-caténine (CTNNB1) est présente dans 1,2 % des mélanomes. Néanmoins, l’impact de cette mutation dans le mélanome reste encore mal connu....
Article
Introduction Le diagnostic d’atteinte leptoméningée (LM) de mélanome est associé à un pronostic sombre avec une médiane de survie historique de 4 à 10 semaines. Bien que le développement de la thérapie ciblée et de l’immunothérapie ait considérablement amélioré le pronostic des patients avec métastases cérébrales de mélanome (MCM), peu de données e...
Article
Introduction Les analyses de génétique somatique sont désormais essentielles dans la prise en charge des patients cancéreux. Dans le mélanome, ces analyses se sont longtemps limitées à l’étude du codon 600 de BRAF, maintenant élargies à une approche « next generation sequencing » (NGS) ciblant plusieurs gènes. Des panels NGS pan-cancer ont ainsi ét...
Article
Introduction L’association nivolumab et ipilimumab (NIVO + IPI) a considérablement amélioré le pronostic des patients avec mélanome métastatique, en particulier en cas de métastases cérébrales. Néanmoins, elle est responsable d’effets indésirables sévères dans environ 55 % des cas. L’objectif de cette étude était d’évaluer en vraie vie une populati...
Article
Introduction Le sarcome de Kaposi (SK) est une maladie lympho-angioproliférative liée au HHV8, qui se caractérise par 4 sous-types cliniques : post-transplantation, épidémique, endémique et classique. Bien que plusieurs études aient décrit l’évolution clinique du SK épidémique et post-transplantation, l’absence de grandes cohortes de SK classique/e...
Article
Introduction L’imatinib mésylate est une alternative à l’exérèse chirurgicale large dans le traitement du DFSP-LA ou métastatique, lorsque la chirurgie n’est pas initialement réalisable. L’objectif de notre étude était d’évaluer le statut à long terme des patients traités par inhibiteurs de tyrosine kinase (TKI) en néoadjuvant pour un DFSP-LA. Mat...
Article
Full-text available
Introduction La question de la prise en charge d’un patient avec un antécédent de mélanome est de plus en plus fréquente. La transplantation d’organe nécessite un traitement immunosuppresseur qui augmente le risque de récidive d’un mélanome antérieur. Peu de recommandations existent concernant la nécessité et la durée d’un délai d’attente avant une...
Article
Introduction Alors que le traitement de la maladie de Kaposi (MK) iatrogénique et épidémique est relativement bien codifié, reposant avant tout sur une restauration des fonctions immunitaires, le traitement optimal de la MK classique/endémique reste à définir. Les patients avec atteinte cutanée étendue ou viscérale sont traités généralement par int...
Article
Dermatofibrosarcoma protuberans (DFSP) is a soft-tissue sarcoma characterized by a high risk of local infiltration. The identification of the COL1A1-PDGFB t(17;22) translocation activating the PDGF pathway led to the use of imatinib in unresectable DFSP, with a response rate of 36–80%. Pazopanib is a multitarget tyrosine kinase inhibitor approved f...
Article
Full-text available
Importance: Few data are available on patients with leptomeningeal disease (LM) from melanoma treated with new systemic therapies. Objective: To gain a better understanding of patients, disease characteristics, and therapeutic interventions in melanoma patients with LM in the era of new systemic treatment. Design: Clinical characteristics, tre...
Preprint
Full-text available
Background: Melanoma brain metastases are the main cause of specific death among patients with metastatic melanoma. The biology of melanoma brain metastases remains largely to be deciphered, as there have been only a few genomic studies on brain metastatic samples. In this study, melanoma metastatic lymph nodes were used with the aim to identify bi...
Article
Background Immune-related hepatitis (IRH) occurs in 1 to 18% of immune checkpoint inhibitor (ICI)-treated patients. Steroids are usually recommended for grade ≥ 3 IRH, but their impact on IRH resolution and patient survival remains unclear. Methods We retrospectively analyzed a prospective cohort of 339 patients treated at Saint-Louis Hospital (Pa...
Article
Full-text available
Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a stu...
Article
Immune checkpoint inhibitors (ICI) have revolutionized the field of oncology, by reshaping the prognosis of many cancers and are progressively becoming the standard of care. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), of which cardiovascular irAEs are particularly feared. ICI-induc...
Article
e22040 Background: Process Mining (PM) is an emerging discipline with promising potential in oncology, which offers a time-oriented perspective on the clinical events that define the patient’s (pts) path of care, from diagnosis to follow-up. PM enables us to 1) build unsupervised models that automatically discover frequent patterns and detect unex...
Article
e15095 Background: ICIs are effective in many tumors, but can cause severe irAEs, with potential long-term impact. Description of irAEs in literature is often insufficient, especially in terms of irAEs duration, and in terms of incidence of late-onset events. Namely, duration of irAEs and proportion of patients (pts) with toxicity still ongoing at...
Article
Full-text available
KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show a de novo resistance in most cases and a limited duration of response when response is achieved. We performed pharmacodynamic studies on patients with KIT-mut...
Article
Cancer is a leading cause of morbidity and deaths in solid organ transplant recipients (SOTR). In immunocompetent patients, cancer prognosis has been dramatically improved with the development of immune checkpoint inhibitors (ICI), as PD1/PDL1 and CTLA4 inhibitors, that increase antitumor immune responses. ICI has been developed outside of the scop...
Article
Objective: The conduct of a medical interview is a challenging skill, even for the most qualified physicians. Since a training is needed to acquire the necessary skills to conduct an interview with a patient, we compared role-play with standardized patients (SP) training and a conventional lecture for the acquisition of communications skills in un...
Article
The most commonly reported pattern of anti-PD-1 induced colitis is an active colitis characterized by neutrophilic inflammation and prominent apoptosis. On the other hand, reports of collagenous colitis (which is a microscopic colitis) are exceptional. In this report, we describe an unusual case of anti-PD1-associated collagenous colitis in a 76-ye...
Article
Background: Deep cutaneous fungal infections (DCFIs) are varied in immunosuppressed patients with few data for such infections in solid-organ transplant recipients (s-OTRs). Objective: To determine DCFIs diagnostic characteristics and outcome with treatments in s-OTRs. Methods: A 20-year retrospective observational study in France was conducte...
Article
Full-text available
The development of BRAF and MEK inhibitors (BRAFi/MEKi) has led to major advances in melanoma treatment. However, the emergence of resistance mechanisms limits the benefit duration and a complete response occurs in less than 20% of patients receiving BRAFi ± MEKi. In this study, we evaluated the impact of an intermittent versus continuous dosing sc...
Article
Purpose of review: Melanoma treatment have been revolutionized since 2010 by the development of immune checkpoint inhibitors, and, for BRAF-mutated melanoma, targeted therapies based on BRAF and MEK inhibitors, which is a model of effective targeted therapy in cancer. However, patients with BRAF wild type cannot benefit for such treatments. In thi...
Article
Introduction Les myopathies inflammatoires induites par l’immunothérapie (MII) sont rares mais potentiellement graves. Leur prise en charge n’est pas standardisée et interroge sur la possibilité de reprise du traitement. L’objectif de cette étude est de préciser les caractéristiques des MII sous anti-PD-1, leur traitement et l’impact d’une reprise...
Article
Introduction Parmi les mécanismes de résistance aux inhibiteurs de BRAF (iBRAF), les effecteurs du cycle cellulaire, notamment CDK4, sont impliqués dans la réactivation de ERK. Dans cette étude de phase I-II multicentrique en ouvert, notre but était d’établir la Dose Maximale Tolérée (DMT) du palbociclib (PB), un inhibiteur de CDK4/6, en associatio...
Article
Introduction L’avènement de l’immunothérapie est associé à la survenue d’événements pancréatiques immuno-induits. L’élévation asymptomatique de la lipase est à distinguer de celle témoignant d’une authentique pancréatite, le plus souvent aiguë (PA), pouvant conduire à l’arrêt du traitement. La PA est définie par la présence d’au moins deux critères...
Article
Introduction Le cémiplimab est le premier anti-programmed cell death 1 (anti-PD1) développé pour les carcinomes épidermoïdes cutanés métastatiques (CECm) et localement avancés (CECla). Le taux de réponse dans l’étude de phase 2 était de 47 %. L’autorisation temporaire d’utilisation (ATU) a été obtenue en France en juillet 2018. Nous décrivons ici l...
Article
Introduction La maladie de Paget (MP) est une tumeur cutanée rare caractérisée par la prolifération de cellules de Paget dans l’épiderme. Alors que la MP mammaire est associée à un cancer du sein dans plus de 90 % des cas, la MP extra-mammaire s’associe à un cancer sous-jacent dans 11 à 30 % des cas. En cas d’atteinte métastatique, le traitement re...
Article
Introduction Le mogamulizumab, anticorps monoclonal anti-CCR4, induit, chez les patients atteints de lymphome T cutané (CTCL) réfractaires à au moins un traitement systémique, une survie sans progression supérieure au vorinostat. Il provoque une déplétion des lymphocytes T régulateurs (Treg) CCR4+, et nous avons récemment rapporté 2 rémissions comp...
Article
Innovative therapeutic strategies in metastatic melanoma depend on molecular features and the combination of BRAF and MEK inhibitors (BRAFi+MEKi) which has recently shown an improved clinical efficacy in BRAFV600MUT metastatic melanoma patients, is now the standard of care. BRAF and NRAS activating mutations lead to the MAPK pathway deregulation1 a...
Article
Background KS is an HHV8 related lympho-angioproliferative disease with 4 clinical settings: post-transplant, epidemic, endemic, and classic. Although several studies described the clinical course of epidemic and post-transplant KS, the lack of large cohorts of C/E KS precluded such characterization. Our study aimed to describe the clinical course...
Article
Background Imatinib mesylate is approved in unresectable tumors and has been also proposed in the neoadjuvant setting in order to reduce tumor size and post-operative relapses for difficult to resect DFSP. The aim of this study was to evaluate the long-term results of neoadjuvant imatinib and other TKI used in DFSP. Methods The files of all patien...
Article
Full-text available
In BRAFV600mut metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previously explored baseline genomic features associated w...
Article
Full-text available
Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogenesis of this melanoma subtype could help us understand the risk factors associated with the development of mucosal melanomas and highlight therapeutic targets. Because the...
Article
The treatment of advanced‐stage cutaneous T‐cell lymphomas (CTCL) is challenging and responses are usually short‐lived. Allogeneic hematopoietic stem cell transplantation (HSCT) provides long‐term remissions in selected patients but requires a pre‐transplant complete remission (CR). Brentuximab vedotin (BV) is an antibody‐drug conjugate that consis...
Article
9545 Background: Among mechanisms of resistance to BRAF inhibitors (BRAFi), cell cycle effectors including CDK4 have been involved in ERK reactivation. In this phase I-II open label study, we aimed to establish the Maximum Tolerated Dose (MTD) of PD0332991, an inhibitor of CDK4/6, when added to vemurafenib (VM) in metastatic melanoma patients. Meth...
Article
Immune checkpoint inhibitors (ICIs) are now the standard of care in the treatment of several cancer types. Cutaneous immune‐related adverse events (irAEs) are usually of low grade and reversible, while endocrine irAEs are generally irreversible and managed with hormone replacement therapy. We report a 47‐year‐old patient treated with the anti‐progr...
Article
Gastrointestinal toxicities of MEK inhibitors in melanoma patients are frequent. In clinical trials, the most common digestive adverse events were nausea, vomiting, and diarrhoea. However, severe toxicities such as colitis and gastrointestinal perforation, some with fatal outcomes, have been reported. These rare but severe adverse events are not we...
Article
The new era of immunotherapy in cancer has led to a dramatical increase in patients survival but also to the emergence of a new type of immune-mediated toxicities mimicking known diseases but with special features. As the spectrum of checkpoint inhibitors is widening to many types of cancer expressing histological signs of immune blockade, new subt...
Article
Dermoscopy was proven more accurate than naked‐eye examination and sequential digital dermoscopy imaging (SDDI) superior to dermoscopy alone for melanoma detection². SDDI combined with total‐body photography (TBP)³ namely the “two‐step method” of digital follow‐up (DFU), seems at present the best surveillance strategy for high risk patients. With t...
Article
Full-text available
Several mechanisms have been described to elucidate the emergence of resistance to MAPK inhibitors in melanoma and there is a crucial need for biomarkers to identify patients who are likely to achieve a better and long-lasting response to BRAF inhibitors therapy. In this study, we developed a targeted approach combining both mRNA and DNA alteration...